For patients with episodic migraine, galcanezumab is better than placebo for reducing migraine headache days.
Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
For individuals with migraine frequency of 4 to 14 episodes per month, prophylactic medications and analgesics are required.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Clinicians need to consider treatments for episodic migraine that may be contraindicated if a patient also has cardiovascular disease.
Future predictive models may need to include other migraine risk factors to enhance predictive accuracy.
Treatment with the monoclonal antibody erenumab reduced the number of monthly migraine days experienced in patients with episodic migraine.
Over 50% of participants reported having an inadequate response to treatment.
Phase 2 results show anti-CGRP receptor monoclonal antibody effective for the prevention of episodic migraine.
Treatment that provides rapid, consistent migraine relief may help mediate factors that promote inadequate treatment response.
Adults taking the drug combo experienced a decreased amount of migraine days compared to placebo.
A simple lipid panel may distinguish those with episodic migraine.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans